Oncternal Therapeutics Inc

NASDAQ:ONCT   3:59:43 PM EDT
4.97
-0.11 (-2.16%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)245.35M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.24 Million
Adjusted EPS-$0.11
See more estimates
10-Day MA$5.53
50-Day MA$6.93
200-Day MA$4.56
See more pivots

Oncternal Therapeutics Inc Stock, NASDAQ:ONCT

12230 El Camino Real, Suite 300, San Diego, California 92130
United States of America
Phone: +1.858.434.1113
Number of Employees: 14

Description

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Cirmtuzumab, TK216, and ROR1 CAR-T. The company was founded by David F. Hale and James B. Breitmeyer in 1997 and is headquartered in San Diego, CA.